- Home
- NBR vs URGN Comparison
NBR vs URGN Comparison
Compare NBR & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBR
- URGN
- Stock Information
- Founded
- NBR 1952
- URGN 2004
- Country
- NBR Bermuda
- URGN United States
- Employees
- NBR N/A
- URGN N/A
- Industry
- NBR Oil & Gas Production
- URGN Biotechnology: Pharmaceutical Preparations
- Sector
- NBR Energy
- URGN Health Care
- Exchange
- NBR Nasdaq
- URGN Nasdaq
- Market Cap
- NBR 445.2M
- URGN 465.9M
- IPO Year
- NBR N/A
- URGN 2017
- Fundamental
- Price
- NBR $29.83
- URGN $9.87
- Analyst Decision
- NBR Hold
- URGN Strong Buy
- Analyst Count
- NBR 7
- URGN 7
- Target Price
- NBR $71.17
- URGN $37.21
- AVG Volume (30 Days)
- NBR 458.9K
- URGN 509.8K
- Earning Date
- NBR 04-29-2025
- URGN 05-12-2025
- Dividend Yield
- NBR N/A
- URGN N/A
- EPS Growth
- NBR N/A
- URGN N/A
- EPS
- NBR N/A
- URGN N/A
- Revenue
- NBR $2,930,126,000.00
- URGN $90,398,000.00
- Revenue This Year
- NBR $13.65
- URGN $38.65
- Revenue Next Year
- NBR $8.29
- URGN $118.69
- P/E Ratio
- NBR N/A
- URGN N/A
- Revenue Growth
- NBR N/A
- URGN 9.29
- 52 Week Low
- NBR $25.11
- URGN $8.94
- 52 Week High
- NBR $105.96
- URGN $20.70
- Technical
- Relative Strength Index (RSI)
- NBR 40.78
- URGN 44.18
- Support Level
- NBR $27.14
- URGN $9.36
- Resistance Level
- NBR $30.25
- URGN $10.51
- Average True Range (ATR)
- NBR 3.15
- URGN 0.69
- MACD
- NBR 0.31
- URGN -0.02
- Stochastic Oscillator
- NBR 59.97
- URGN 49.21
About NBR Nabors Industries Ltd.
Nabors Industries Ltd owns and operates land-based drilling rig fleets and is a provider of offshore platform rigs in the United States and international markets. It also provides performance tools, directional drilling services, tubular running services, and technologies. The company has four reportable segments: U.S. Drilling, International Drilling, Drilling Solutions, and Rig Technologies. The key revenue of the company is generated from International Drilling.
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.